Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Pathology
October 25, 2016
The omens look good for a medtech-only Philips
September 07, 2016
Event – Celgene takes a deeper look in Crohn’s
August 01, 2016
Ionis Endears itself to investors – and to Biogen
March 04, 2016
Interview – TxCell chases the next next big thing after CAR-T
October 28, 2015
GE downplays Clarient sale
July 01, 2015
Sembragiline grounds into a triple play
March 20, 2015
Lilly snares rare BTK inhibitor but hints at different path foward
June 30, 2014
Desmoteplase fail vindicates Paion’s exit
November 29, 2013
EP Vantage interview – Covance puts the pieces of the puzzle together
May 22, 2013
Search continues for biomarkers to aid Huntington’s research
September 29, 2011
Therapeutic Focus - Diabetic foot ulcer market in need of healing
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 20, 2020
Vantage Pharma, Biotech & Medtech 2019 in Review
December 17, 2019
Vantage 2020 Preview
Editor's Picks
January 28, 2020
The cost to Astrazeneca of building Brilinta
January 27, 2020
Rare diseases top another strong year for novel drug approvals
January 07, 2020
Surprise! There’s a tumour in which Keytruda doesn’t work
January 16, 2020
A quiet six months for device approvals
January 22, 2020
Sanofi's geriatric pipeline fails to freshen up
